OTCMKTS:ATBPF
Antibe Therapeutics Inc Stock News
$0.216
+0 (+0%)
At Close: May 10, 2024
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
07:00am, Thursday, 07'th Mar 2024
TORONTO--(BUSINESS WIRE)---- $ATBPF--ANTIBE TO PRESENT OTENAPROXESUL PK/PD RESULTS AT THE AMERICAN ACADEMY OF PAIN MEDICINE MEETING.
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
07:00am, Tuesday, 06'th Sep 2022
TORONTO--(BUSINESS WIRE)---- $ATBPF--Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
Antibe Therapeutics (TSE:ATE) Hits New 12-Month Low at $0.73
06:54pm, Monday, 29'th Nov 2021 Transcript Daily
Antibe Therapeutics Inc. (TSE:ATE)s stock price reached a new 52-week low during mid-day trading on Monday . The company traded as low as C$0.73 and last traded at C$0.73, with a volume of 17440 shares traded. The stock had previously closed at C$0.74. Several brokerages have recently weighed in on ATE. Maxim Group reduced their []
Insider Buying: Antibe Therapeutics Inc. (TSE:ATE) Director Acquires C$45,000.00 in Stock
03:00pm, Friday, 19'th Nov 2021 Dakota Financial News
Antibe Therapeutics Inc. (TSE:ATE) Director Walter Minnes Macnee acquired 50,000 shares of Antibe Therapeutics stock in a transaction dated Wednesday, November 10th. The stock was purchased at an average price of C$0.90 per share, with a total value of C$45,000.00. Following the completion of the purchase, the director now owns 497,027 shares of the companys []
Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Given Consensus Rating of Buy by Analysts
05:54pm, Thursday, 18'th Nov 2021 Transcript Daily
Antibe Therapeutics Inc. (OTCMKTS:ATBPF) has earned a consensus rating of Buy from the six analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have issued []
